Xian-Jun Yu
Overview
Explore the profile of Xian-Jun Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xing F, Li B, Fang Y, Liang C, Liu J, Wang W, et al.
Acta Pharmacol Sin
. 2024 Sep;
46(2):474-488.
PMID: 39289547
Pancreatic ductal adenocarcinoma (PDAC) is distinguished by its aggressive malignancy, limited treatment avenues and a tendency towards chemotherapy resistance, underscoring the critical need for advanced research to uncover new therapeutic...
2.
Zhang H, Li T, Yu X, Liu C, Wu W, Ye L, et al.
Cell Death Dis
. 2024 Apr;
15(4):244.
PMID: 38575607
The immunosuppressive microenvironment caused by several intrinsic and extrinsic mechanism has brought great challenges to the immunotherapy of pancreatic cancer. We identified GFPT2, the key enzyme in hexosamine biosynthesis pathway...
3.
Liu Y, Tang R, Meng Q, Shi S, Xu J, Yu X, et al.
BMC Cancer
. 2024 Jan;
24(1):87.
PMID: 38229038
Background: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, and its molecular mechanisms are unclear. Nucleolar and spindle-associated protein 1 (NUSAP1), an indispensable mitotic regulator, has been reported to be...
4.
Chen H, Ye Z, Hu H, Fan G, Hu Y, Li Z, et al.
Acta Pharmacol Sin
. 2023 Dec;
45(4):844-856.
PMID: 38057506
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy prone to recurrence and metastasis. Studies show that tumor cells with increased invasive and metastatic potential are more likely to undergo...
5.
Li T, Jin K, Zhou H, Liao Z, Zhang H, Shi S, et al.
Cancer Lett
. 2023 Sep;
576:216411.
PMID: 37757903
Pancreatic ductal adenocarcinoma (PDAC) is extremely malignant with limited treatment options. Deubiquitinases (DUBs), which cleave ubiquitin on substrates, can regulate tumor progression and are appealing therapeutic targets, but there are...
6.
Jin K, Wu Y, Zheng X, Li T, Liao Z, Fei Q, et al.
FEBS J
. 2023 May;
290(18):4577-4590.
PMID: 37245155
Intrinsic drug resistance mechanisms of tumor cells often reduce intracellular drug concentration to suboptimal levels. Epithelial-to-mesenchymal transition (EMT) is a pivotal process in tumor progression and metastasis that confers an...
7.
Hu H, Hu Y, Xu X, Ye Z, Lou X, Zhang W, et al.
Pancreas
. 2023 Apr;
51(10):1404-1410.
PMID: 37099786
Objectives: Somatostatin receptors are commonly expressed in most pancreatic neuroendocrine tumors (pNETs), a rare type of pancreatic tumors with high heterogeneity. However, the role of somatostatin receptor 2 (SSTR2) has...
8.
Lu S, Hua J, Liu J, Wei M, Liang C, Meng Q, et al.
Comput Struct Biotechnol J
. 2023 Apr;
21:2419-2433.
PMID: 37090434
Growing evidence indicates a potential correlation between necroptosis and pancreatic cancer, and the relationship between necroptosis, immune infiltration and the microenvironment in pancreatic cancer has drawn increasing attention. However, two-dimensional...
9.
Wang T, Ye Z, Li Z, Jing D, Fan G, Liu M, et al.
Cell Prolif
. 2023 Apr;
56(10):e13478.
PMID: 37060186
Lactate is not only an endpoint of glycolysis but is gradually being discovered to play the role of a universal metabolic fuel for energy via the 'lactate shuttle' moving between...
10.
Zhang W, Xu J, Hu Y, Qin Y, Chen J, Yu X, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046616
Background: This study aimed to summarize the surgical and therapeutic activities of non-functional pancreatic neuroendocrine tumors (NF-PanNETs) and perform survival analyses of a 15-year single-institutional cohort of NF-PanNETs. Methods: In...